Consequently, zebrafish were employed in the present study to assess the therapeutic effects of apoA-I in combination with CIGB-258 against CML-induced chronic wounds and dyslipidemia. This evidence concerns the gene APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive.